Sovereign Pharms Drug Patent Portfolio
Sovereign Pharms owns 1 orange book drug protected by 3 US patents Given below is the list of Sovereign Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10105324 | Immediate release oral guaifenesin solution | 13 Nov, 2035 | Active |
| US9549907 | Immediate release oral guaifenesin solution | 13 Nov, 2035 | Active |
| US9808431 | Immediate release oral guaifenesin solution | 13 Nov, 2035 | Active |
Latest Legal Activities on Sovereign Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sovereign Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Jul, 2024 | US9549907 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 May, 2024 | US9549907 |
|
Email Notification
Critical
| 03 Aug, 2022 | US10105324 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 03 Aug, 2022 | US9808431 |
|
Email Notification
Critical
| 03 Aug, 2022 | US9549907 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 03 Aug, 2022 | US9549907 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 03 Aug, 2022 | US10105324 |
|
Email Notification
Critical
| 03 Aug, 2022 | US9808431 |
|
Correspondence Address Change
Critical
| 01 Aug, 2022 | US10105324 |
|
Correspondence Address Change
Critical
| 01 Aug, 2022 | US9549907 |
|
Correspondence Address Change
Critical
| 01 Aug, 2022 | US9808431 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 06 Apr, 2022 | US10105324 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 04 May, 2021 | US9808431 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 22 Jul, 2020 | US9549907 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 23 Oct, 2018 | US10105324 |
Sovereign Pharms's Family Patents
Sovereign Pharms drugs have patent protection in a total of 1 countries. It has a significant patent presence in the US with 100.0% of its patents being US patents. Click
below to unlock the full patent family tree.
Sovereign Pharms Drug List
Given below is the complete list of Sovereign Pharms's drugs and the patents protecting them.
1. Obredon
Obredon is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10105324 | Immediate release oral guaifenesin solution |
13 Nov, 2035
(11 years from now)
| Active |
| US9549907 | Immediate release oral guaifenesin solution |
13 Nov, 2035
(11 years from now)
| Active |
| US9808431 | Immediate release oral guaifenesin solution |
13 Nov, 2035
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Obredon's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List